47 ud af 47 tidsskrifter valgt, søgeord (influenza) valgt, emner højest 180 dage gamle, sorteret efter nyeste først.
201 emner vises.
101
Highly pathogenic avian influenza H5N1 virus infection of companion animals
Hinh LyDepartment of Veterinary & Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Twin Cities, MN, USA
Virulence, 8.01.2024
Tilføjet 8.01.2024
102
Metabolomic Signatures Differentiate Immune Responses in Avian Influenza Vaccine Recipients
Journal of Infectious Diseases, 5.01.2024
Tilføjet 5.01.2024
Abstract Background Avian influenza viruses pose significant risk to human health. Vaccines targeting the hemagglutinin of these viruses are poorly immunogenic without the use of adjuvants.Methods Twenty healthy men and women (18-49 years of age) were randomized to receive two doses of inactivated influenza A/H5N1 vaccine alone (IIV) or with AS03 adjuvant (IIV-AS03) one month apart. Urine and serum samples were collected on day 0 and on days 1, 3, and 7 following first vaccination and subjected to metabolomics analyses to identify metabolites, metabolic pathways, and metabolite clusters associated with immunization.Results Seventy-three differentially abundant (DA) serum and 88 urine metabolites were identified for any post-vaccination day comparison. Pathway analysis revealed enrichment of tryptophan, tyrosine and nicotinate metabolism in urine and serum among IIV-AS03 recipients. Increased urine abundance of 4-vinylphenol sulfate on Day 1 was associated with serologic response based on hemagglutination inhibition responses. In addition, 9 DA urine metabolites were identified in participants with malaise compared to those without.Conclusions Our findings suggest that tryptophan, tyrosine, and nicotinate metabolism are upregulated among IIV-AS03 recipients compared with IIV alone. Metabolites within these pathways may serve as measures of immunogenicity and may provide mechanistic insights for adjuvanted vaccines.
Læs mere
Tjek på PubMed
103
Recombinant duck enteritis virus bearing the hemagglutinin genes of H5 and H7 influenza viruses is an ideal multivalent live vaccine in ducks
Yubo ZhaoPucheng ChenYuzhen HuJing LiuYongping JiangXianying ZengGuohua DengJianzhong ShiYanbing LiGuobin TianJinxiong LiuHualan Chena State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, People’s Republic of Chinab National Poultry Laboratory Animal Resource Center, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, People’s Republic of China
Emerg Microbes Infect, 5.01.2024
Tilføjet 5.01.2024
104
Evolution and biological characterization of H5N1 influenza viruses bearing the clade 2.3.2.1 hemagglutinin gene
Xin XingJianzhong ShiPengfei CuiCheng YanYaping ZhangYuancheng ZhangCongcong WangYuan ChenXianying ZengGuobin TianLiling LiuYuntao GuanChengjun LiYasuo SuzukiGuohua DengHualan Chena State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, CAAS, Harbin, People’s Republic of Chinab Guangdong Laboratory for Lingnan Modern Agriculture, Guangzhou, People’s Republic of Chinac Institute of Western Agriculture, CAAS, Changji, People’s Republic of Chinad National Poultry Laboratory Animal Resource Center, Harbin Veterinary Research Institute, CAAS, Harbin, People’s Republic of Chinae Department of Medical Biochemistry, University of Shizuoka School of Pharmaceutical Sciences, Shizuoka, Japan
Emerg Microbes Infect, 5.01.2024
Tilføjet 5.01.2024
105
Reducing Diagnostic Bias Through Multiplex Polymerase Chain Reaction (PCR) Testing for SARS-CoV-2, Influenza A/B, and RSV
Clinical Infectious Diseases, 4.01.2024
Tilføjet 4.01.2024
106
Outcomes of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant, Influenza, and Respiratory Syncytial Virus on the Dissecting Table: Is Further Dissection Required?
Clinical Infectious Diseases, 4.01.2024
Tilføjet 4.01.2024
To the Editor—We read with interest the article by Hedberg et al that describes the differences in disease severity and outcomes following infections with the severe acute respiratory syndrome coronavirus 2 Omicron variant, influenza, and respiratory syncytial virus (RSV) among adult outpatients and inpatients [1]. The article provided important information and indicated that the Omicron variant is associated with worse outcomes compared with RSV and influenza. We would like to offer some insights that we believe could further enhance the comprehension and context of the study’s findings.
Læs mere
Tjek på PubMed
107
The chemokine receptor CXCR3 promotes CD8+ T cell–dependent lung pathology during influenza pathogenesis
Kai Guo, Dan J. K. Yombo, Zhihan Wang, Zahrasadat Navaeiseddighi, Jintao Xu, Taylor Schmit, Nassem Ahamad, Jitendra Tripathi, Bony De Kumar, Ramkumar Mathur, Junguk Hur, Jie Sun, Michal A. Olszewski, Nadeem Khan
Science Advances, 4.01.2024
Tilføjet 4.01.2024
108
WHO: Surge in Respiratory Infections in China Not Due to New Pathogens
Journal of the American Medical Association, 3.01.2024
Tilføjet 3.01.2024
Respiratory illnesses—including Mycoplasma pneumoniae pneumonia, respiratory syncytial virus (RSV), and influenza—have been on the rise among children in China over the past several months.
Læs mere
Tjek på PubMed
109
NSAID prescribing and adverse outcomes in common infections: a population-based cohort study
Stuart, B., Venekamp, R., Hounkpatin, H., Wilding, S., Moore, M., Little, P., Gulliford, M. C.
BMJ Open, 3.01.2024
Tilføjet 3.01.2024
ObjectivesInfections in primary care are often treated with non-steroidal anti-inflammatory drugs (NSAIDs). This study evaluates whether NSAID prescribing is associated with adverse outcomes for respiratory (RTIs) or urinary track (UTI) infections. ObjectivesTo determine whether there is an association between NSAID prescribing and the rate of adverse outcomes for infections for individual consulting in primary care. DesignCohort study of electronic health records. Setting87 general practices in the UK Clinical Practice Research Datalink GOLD. Participants142 925 patients consulting with RTI or UTI. Primary and secondary outcome measuresRepeat consultations, hospitalisation or death within 30 days of the initial consultation for RTI or UTI. Poisson models estimated the associations between NSAID exposure and outcome. Rate ratios were adjusted for gender, age, ethnicity, deprivation, antibiotic use, seasonal influenza vaccination status, comorbidities and general practice. Since prescribing variations by practice are not explained by case mix—hence, less impacted by confounding by indication—both individual-level and practice-level analyses are included. ResultsThere was an increase in hospital admission/death for acute NSAID prescriptions (RR 2.73, 95% CI 2.10 to 3.56) and repeated NSAID prescriptions (6.47, 4.46–9.39) in RTI patients, and for acute NSAID prescriptions for UTI (RR 3.03; 1.92 to 4.76). Practice-level analysis, controlling for practice population characteristics, found that for each percentage point increase in NSAID prescription, the percentages of hospital admission/death within 30 days increased by 0.32 percentage points (95% CI 0.16 to 0.47). ConclusionsIn this non-randomised study, prescription of NSAIDs at consultations for RTI or UTIs in primary care is infrequent but may be associated with increased risk of hospital admission. This supports other observational and limited trial data that NSAID prescribing might be associated with worse outcomes following acute infection and should be prescribed with caution.
Læs mere
Tjek på PubMed
110
Protective human antibodies against a conserved epitope in pre- and postfusion influenza hemagglutinin
Joel FinneyAnnie Park MosemanSusan KongAkiko WatanabeShengli SongRichard M. WalshMasayuki KuraokaRyutaro KotakiE. Ashley MosemanKevin R. McCarthyDongmei LiaoXiaoe LiangXiaoyan NieOlivia LavidorRichard AbbottStephen C. HarrisonGarnett KelsoeaLaboratory of Molecular Medicine, Children’s Hospital, Harvard Medical School, Boston, MA 02115bDepartment of Integrative Immunobiology, Duke University, Durham, NC 27710cDepartment of Surgery, Duke University, Durham, NC 27710dThe Harvard Cryo-Electron Microscopy (Cryo-EM) Center for Structural Biology, Harvard Medical School, Boston, MA 02115eDepartment of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115fCenter for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261gHHMI, Boston, MA 02115hDuke Human Vaccine Institute, Duke University, Durham, NC 27710
Proceedings of the National Academy of Sciences, 3.01.2024
Tilføjet 3.01.2024
111
[Editorial] Patterns of respiratory infections after COVID-19
The Lancet Respiratory Medicine
Lancet Respiratory Medicine, 3.01.2024
Tilføjet 3.01.2024
Changing patterns of respiratory infections have been seen again in 2024. Disease incidence shifted during the COVID-19 pandemic due to lockdowns and social distancing, which slowed down pathogen circulation and the development of immunity at a population level. Influenza and RSV have settled into a more traditional pattern this year, but tuberculosis and pneumonia incidence remains unusual.
Læs mere
Tjek på PubMed
112
Epidemiological trends of respiratory tract pathogens detected via mPCR in Australian adult patients before COVID-19
BMC Infectious Diseases, 2.01.2024
Tilføjet 2.01.2024
Abstract Background Respiratory tract infections (RTIs) are a major global health burden due to their high morbidity and mortality. This retrospective study described the epidemiology of respiratory pathogens in adults over a 5-year period at an Australian tertiary healthcare network. Methods All multiplex reverse transcription polymerase chain reaction respiratory samples taken between the 1st of November 2014 and the 31st of October 2019 were included in this study. Overall prevalence and variations according to seasons, age groups and sex were analysed, as well as factors associated with prolonged hospital and intensive care length of stay. Results There were 12,453 pathogens detected amongst the 12,185 positive samples, with coinfection rates of 3.7%. Picornavirus (Rhinovirus), Influenza A and respiratory syncytial virus were the most commonly detected pathogens. Mycoplasma pneumoniae was the most commonly detected atypical bacteria. Significant differences in the prevalence of Chlamydia pneumoniae and Human metapneumovirus infections were found between sexes. Longest median length of intensive care and hospital stay was for Legionella species. Seasonal variations were evident for certain pathogens. Conclusions The high rates of pathogen detection and hospitalisation in this real-world study highlights the significant burden of RTIs, and the urgent need for an improved understanding of the pathogenicity as well as preventative and treatment options of RTIs.
Læs mere
Tjek på PubMed
113
Severe pneumonia with co-infection of H5N1 and SARS-CoV-2: a case report
BMC Infectious Diseases, 2.01.2024
Tilføjet 2.01.2024
Abstract Background The H5N1 influenza virus is a cause of severe pneumonia. Co-infection of influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may lead to poor prognosis of patients during the COVID-19 epidemic. However, reports on patients co-infected with avian influenza virus and SARS-CoV-2 are scarce. Case presentation A 52-year-old woman presented with a fever, which has persisted for the past eight days, along with worsening shortness of breath and decreased blood pressure. Computed tomography (CT) revealed an air bronchogram, lung consolidation, and bilateral pleural effusion. The subsequent polymerase chain reaction (PCR) of the bronchoalveolar lavage fluid (BALF) revealed positivity for H5N1 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Conclusion The H5N1 influenza virus is a cause of severe pneumonia. The clinical presentation of the patient had a predomination of H5N1 influenza rather than COVID-19. A PCR analysis for the identification of the virus is necessary to reveal the pathogen causing the severe pneumonia. The patient exhibited an excellent prognosis upon the use of the appropriate antiviral medicine.
Læs mere
Tjek på PubMed
114
Vaccination against influenza viruses reduces infection, not hospitalization or death, from respiratory COVID‐19: A systematic review and meta‐analysis
Antonio E. Pontiroli, Francesco Scovenna, Valentina Carlini, Elena Tagliabue, Jimmy Martin‐Delgado, Lucia La Sala, Elisabetta Tanzi, Ivan Zanoni
Journal of Medical Virology, 2.01.2024
Tilføjet 2.01.2024
115
A single immunization with H5N1 virus-like particle vaccine protects chickens against divergent H5N1 influenza viruses and vaccine efficacy is determined by adjuvant and dosage
Dexin KongYanjuan HeJiaxin WangLanyan ChiXiang AoHejia YeWeihong QiuXiutong ZhuMing LiaoHuiying Fana College of Veterinary Medicine, South China Agricultural University, Guangzhou, People’s Republic of Chinab Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou, People’s Republic of Chinac Key Laboratory of Veterinary Vaccine Innovation of the Ministry of Agriculture and Rural Affairs, Guangzhou, People’s Republic of Chinad National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, Guangzhou, People’s Republic of Chinae Guangzhou South China Biological Medicine Co., Ltd, Guangzhou, People’s Republic of China
Emerg Microbes Infect, 31.12.2023
Tilføjet 31.12.2023
116
Influenza viral infection is a risk factor for severe illness in COVID-19 patients: a nationwide population-based cohort study
Jeong-Hwan HwangYeon Seok YouSang Woo YeomMin Gyu LeeJong-hwan LeeMin Gul KimJong Seung Kima Department of Internal Medicine, Division of Infectious Diseases, Jeonbuk National University Medical School, Jeonju, South Koreab Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, South Koreac Department of Medical Informatics, Jeonbuk National University, Jeonju, South Koread Department of Otorhinolaryngology, Jeonbuk National University Medical School, Jeonju, South Koreae Department of Pharmacology, Jeonbuk National University Medical School, Jeonju, South Korea
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
117
Risk assessment of the newly emerged H7N9 avian influenza viruses
Pengxiang ChangJean-Remy SadeyenSushant BhatRebecca DainesAltaf HussainHuseyin YilmazMunir Iqbala The Pirbright Institute, Woking, UKb Department of Virology, Veterinary Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
118
Cross-species infection potential of avian influenza H13 viruses isolated from wild aquatic birds to poultry and mammals
Weiyang SunMenglin ZhaoZhijun YuYuanguo LiXinghai ZhangNa FengTiecheng WangHongmei WangHongbin HeYongkun ZhaoSongtao YangXianzhu XiaYuwei Gaoa Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Chang’chun, People’s Republic of Chinab Poultry Institute, Shandong Academy of Agricultural Sciences, Ji’nan, People’s Republic of Chinac Key Laboratory of Animal Resistant Biology of Shandong, Ruminant Disease Research Center, College of Life Science, Shandong Normal University, Ji’nan, People’s Republic of Chinad Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yang’zhou, People’s Republic of China
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
119
Bivalent vaccines effectively protect mice against influenza A and respiratory syncytial viruses
Sathya N. Thulasi RamanAdrian ZetnerAnwar M. HashemDevina PatelJianguo WuCaroline GravelJun GaoWanyue ZhangAnnabelle PfeifleLevi TammingKaran ParikhJingxin CaoRoger TamDavid SafronetzWangxue ChenMichael J.W. JohnstonLisheng WangSimon SauveMichael Rosu-MylesGary Van DomselaarXuguang Lia Centre for Oncology and Regulatory Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canadab National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canadac Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabiad Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabiae Human Health Therapeutics Research Center, National Research Council of Canada, Ottawa, Canadaf Department of Chemistry, Carleton University, Ottawa, Canadag Centre for Vaccines Clinical Trials and Biostatistics, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, Canadah Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
120
Reciprocal enhancement of SARS-CoV-2 and influenza virus replication in human pluripotent stem cell-derived lung organoids
Min Jung KimSumi KimHeeyeon KimDayeon GilHyeong-Jun HanRajesh K. ThimmulappaJang-Hoon ChoiJung-Hyun Kima Division of Intractable Diseases Research, Department of Chronic Diseases Convergence Research, Korea National Institute of Health, Cheongju, Koreab Korea National Stem Cell Bank, Cheongju, South Koreac Division of Acute Viral Disease, Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Cheongju, Koread Department of Biochemistry, Center of Excellence in Molecular Biology and Regenerative Medicine, JSS Medical College, JSS Academy of Higher Education & Research, Mysuru, India
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
121
Cell-intrinsic genomic reassortment of pandemic H1N1 2009 and Eurasian avian-like swine influenza viruses results in potentially zoonotic variants
Verónica A. FerrandoMarcel E. FriedrichShrey GandhiAlexander MellmannDörthe MasemannAnmari ChristerssonDarisuren AnhlanLinda BrunotteMonika StollTimm HarderMartin BeerYvonne BoergelingStephan Ludwiga Institute of Virology Münster, Westfälische Wilhelms-University, Münster, Germanyb Department of Genetic Epidemiology, Institute of Human Genetics, Westfälische Wilhelms-University, Münster, Germanyc Institute of Hygiene Münster, Westfälische Wilhelms-University, Münster, Germanyd Institute of Diagnostic Virology, Friedrich-Loeffler-Institute, Greifswald, Germany
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
122
Mixed selling of different poultry species facilitates emergence of public-health-threating avian influenza viruses
Zhen WangHongkui LiYuhan LiZhuanli WuHui AiMing ZhangLibin RongMichael L. BlinovQi TongLitao LiuHonglei SunJuan PuWenhai FengJinhua LiuYipeng Suna National Key Laboratory of Veterinary Public Health Security, Key Laboratory for Prevention and Control of Avian Influenza and Other Major Poultry Diseases and Key Laboratory of Animal Epidemiology of Ministry of Agriculture and Rural Affairs, College of Veterinary Medicine, China Agricultural University, Beijing, People’s Republic of Chinab State Key Laboratories of Agrobiotechnology, and Department of Microbiology and Immunology, College of Biological Science, China Agricultural University, Beijing, People’s Republic of Chinac Liaoning Agricultural Development Service Center, Shenyang, People’s Republic of Chinad Department of Epidemiology and Biostatistics, University of Georgia, Athens, GA, USAe Department of Mathematics, University of Florida, Gainesville, FL, USAf Center for Cell Analysis and Modeling, University of Connecticut School of Medicine, Farmington, CT, USA
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
123
Genetic, biological and epidemiological study on a cluster of H9N2 avian influenza virus infections among chickens, a pet cat, and humans at a backyard farm in Guangxi, China
Jing YangJianhua YanCheng ZhangShanqin LiManhua YuanChunge ZhangChenguang ShenYang YangLifeng FuGuanlong XuWeifeng ShiZhenghai MaTing Rong LuoYuhai Bia CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing, People’s Republic of Chinab Laboratory of Animal Infectious Diseases, Medical College & College of Animal Sciences and Veterinary Medicine, Guangxi University, Nanning, People’s Republic of Chinac College of Life Science and Technology, Xinjiang University, Urumchi, People’s Republic of Chinad Shenzhen Key Laboratory of Pathogen and Immunity, Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious Diseases, State Key Discipline of Infectious Disease, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of Chinae School of Public Health, Southern Medical University, Guangzhou, People’s Republic of Chinaf China Institute of Veterinary Drug Control, Beijing, People’s Republic of Chinag Key Laboratory of Etiology and Epidemiology of Emerging Infectious Diseases in Universities of Shandong, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, People’s Republic of Chinah University of Chinese Academy of Sciences, Beijing, People’s Republic of China
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
124
Epidemiology, evolution, and biological characteristics of H6 avian influenza viruses in China
Xiaohao XuQi ChenMin TanJia LiuXiyan LiLei YangYuelong ShuDayan WangWenfei Zhua School of Public Health (Shenzhen), Sun Yat-sen University, Guangdong, People’s Republic of Chinab National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; WHO Collaborating Center for Reference and Research on Influenza; Key Laboratory for Medical Virology, National Health and Family Planning Commission, Beijing, People’s Republic of Chinac Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of China
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
125
Influenza vaccination is associated with a reduced risk of invasive aspergillosis in high-risk individuals in Taiwan: a population-based cohort study
Yi-Jyun ChenI-Feng LinJen-Hsiang ChuangHung-Ling HuangTa-Chien Chana Institute of Public Health, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwanb Centers for Disease Control, Taipei, Taiwanc Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung, Taiwand Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwane Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwanf Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwang Research Center for Humanities and Social Sciences, Academia Sinica, Taipei, Taiwan
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
126
Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
Hongjie XiaJason YeungBirte KalveramCody J. BillsJohn Yun-Chung ChenChaitanya KurhadeJing ZouSteven G. WidenBrian R. MannRebecca KondorC. Todd DavisBin ZhouDavid E. WentworthXuping XiePei-Yong Shia Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USAb Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USAc Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USAd Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX, USAe Sealy, Institute for Drug Discovery, University of Texas Medical Branch, Galveston, TX, USAf Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USAg Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USAh Sealy Center for Structural Biology & Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USA
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
127
Prevalence, evolution, replication and transmission of H3N8 avian influenza viruses isolated from migratory birds in eastern China from 2017 to 2021
Yanwen WangMengjing WangHong ZhangConghui ZhaoYaping ZhangJinyan ShenXiaohong SunHongke XuYujiao XieXinxin GaoPengfei CuiDong ChuYubao LiWenqiang LiuPeng PengGuohua DengJing GuoXuyong Lia College of Agronomy, Liaocheng University, Liaocheng, People’s Republic of Chinab Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, State Key Laboratory of Veterinary Biotechnology, National Poultry Laboratory Animal Resource Center, Harbin, People’s Republic of Chinac Biological Disaster Control and Prevention Center, National Forestry and Grassland Administration, Shenyang, People’s Republic of China
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
128
Development of an mRNA vaccine against a panel of heterologous H1N1 seasonal influenza viruses using a consensus hemagglutinin sequence
Ning MaZhi-Wu XiaZhe-Gang ZhangXuan-Xuan NianXue-Dan LiZheng GongGuo-Mei ZhangYang LeRong ZhouJia-You ZhangXiao-Ming Yanga National Engineering Technology Research Center for Combined Vaccines, Wuhan, People’s Republic of Chinab The Second Laboratory of Viral Vaccine Research, Wuhan Institute of Biological Products Co. Ltd., Wuhan, People’s Republic of Chinac School of Animal Science and Technology, School of Animal Medicine, Huazhong Agricultural University, Wuhan, People’s Republic of Chinad China National Biotec Group Company Limited, Beijing, People’s Republic of China
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
129
Diverse infectivity, transmissibility, and pathobiology of clade 2.3.4.4 H5Nx highly pathogenic avian influenza viruses in chickens
Jung-Hoon KwonKateri BertranDong-Hun LeeMiria Ferreira CriadoLindsay KillmasterMary J. Pantin-JackwoodDavid E. Swaynea Agricultural Research Service, U.S. Department of Agriculture, U.S. National Poultry Research Center, Athens, GA, USAb College of Veterinary Medicine, Kyungpook National University, Daegu, Republic of Koreac Unitat mixta d’Investigació IRTA-UAB en Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), Bellaterra, Spaind IRTA. Programa de Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), Bellaterra, Spaine College of Veterinary Medicine, Konkuk University, Seoul, Republic of Koreaf Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, USA
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
130
Highly pathogenic avian influenza H5N1 virus outbreak among Cape cormorants (Phalacrocorax capensis) in Namibia, 2022
Umberto MoliniJohn YabeIrene K. MekiHatem Ouled Ahmed Ben AliTirumala B. K. SettypalliSneha DattaLauren Michelle CoetzeeEllini HamunyelaSiegfried KhaisebGiovanni CattoliCharles E. LamienWilliam G. Dundona School of Veterinary Medicine, Faculty of Health Sciences and Veterinary Medicine, University of Namibia, Windhoek, Namibiab Central Veterinary Laboratory (CVL), Windhoek, Namibiac Animal Production and Health Laboratory, Animal Production and Health Section, Department of Nuclear Sciences and Applications, Joint FAO/IAEA Division, International Atomic Energy Agency, Vienna, Austria
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
131
Emerging triple-reassortant influenza C virus with household-associated infection during an influenza A(H3N2) outbreak, China, 2022
Lan CaoYing LuChaojun XieYiyun ChenLijun LiangTengfei ZhouZiyi ZengChen WenBiao DiBaisheng LiKuibiao LiZhoubin Zhanga Institute of Public Health, Guangzhou Medical University and Guangzhou Center for Disease Control and Prevention, Guangzhou, People’s Republic of Chinab Huadu District Center for Disease Control and Prevention, Guangzhou, People’s Republic of Chinac Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, People’s Republic of China
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
132
Alarming situation of emerging H5 and H7 avian influenza and effective control strategies
Jianzhong ShiXianying ZengPengfei CuiCheng YanHualan Chena Guangdong Laboratory for Lingnan Modern Agriculture, Guangzhou, People’s Republic of Chinab State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, CAAS, Harbin, People’s Republic of China
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
133
A Multi-Season Randomised Controlled Trial of Advax-Adjuvanted Seasonal Influenza Vaccine in Participants with Chronic Disease or Older Age
Journal of Infectious Diseases, 29.12.2023
Tilføjet 29.12.2023
Abstract Background The aim of this study was to determine the safety and immunogenicity of trivalent inactivated influenza vaccine (TIV) alone or formulated with Advax™ delta inulin adjuvant in those of older age (> 60 years) or with chronic disease.Methods Over four consecutive years from 2008-2011, adult participants with chronic disease or over 60 years were recruited into a randomised controlled study to assess the safety, tolerability and immunogenicity of Advax-adjuvanted versus standard TIV. The per protocol (PP) population with at least one post-baseline measurement of influenza antibodies comprised 1297 participants: 447 in the TIV, and 850 in the Advax-adjuvanted TIV, groups.Results No safety issues were identified. Variables negatively affecting vaccine responses included obesity and diabetes mellitus. Advax adjuvant had a positive impact on anti-influenza IgM responses and on H3N2 and B strain seropositivity as assessed by hemagglutination inhibition.Conclusions Advax-adjuvanted TIV was safe and well tolerated in individuals with chronic disease. There is an ongoing need for research into improved influenza vaccines for high-risk populations. Australia New Zealand Clinical Trial Registry: ACTRN 12608000364370.
Læs mere
Tjek på PubMed
134
Protective human antibodies against a conserved epitope in pre- and postfusion influenza hemagglutinin
Joel FinneyAnnie Park MosemanSusan KongAkiko WatanabeShengli SongRichard M. WalshMasayuki KuraokaRyutaro KotakiE. Ashley MosemanKevin R. McCarthyDongmei LiaoXiaoe LiangXiaoyan NieOlivia LavidorRichard AbbottStephen C. HarrisonGarnett KelsoeaLaboratory of Molecular Medicine, Children’s Hospital, Harvard Medical School, Boston, MA 02115bDepartment of Integrative Immunobiology, Duke University, Durham, NC 27710cDepartment of Surgery, Duke University, Durham, NC 27710dThe Harvard Cryo-Electron Microscopy (Cryo-EM) Center for Structural Biology, Harvard Medical School, Boston, MA 02115eDepartment of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115fCenter for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261gHHMI, Boston, MA 02115hDuke Human Vaccine Institute, Duke University, Durham, NC 27710
Proceedings of the National Academy of Sciences: Immunology and Inflammation, 27.12.2023
Tilføjet 27.12.2023
135
Evaluation and clinical practice of pathogens and antimicrobial resistance genes of BioFire FilmArray Pneumonia panel in lower respiratory tract infections
Infection, 23.12.2023
Tilføjet 23.12.2023
Abstract Background Existing panels for lower respiratory tract infections (LRTIs) are slow and lack quantification of important pathogens and antimicrobial resistance, which are not solely responsible for their complex etiology and antibiotic resistance. BioFire FilmArray Pneumonia (PN) panels may provide rapid information on their etiology. Methods The bronchoalveolar lavage fluid of 187 patients with LRTIs was simultaneously analyzed using a PN panel and cultivation, and the impact of the PN panel on clinical practice was assessed. The primary endpoint was to compare the consistency between the PN panel and conventional microbiology in terms of etiology and drug resistance, as well as to explore the clinical significance of the PN panel. The secondary endpoint was pathogen detection using the PN panel in patients with community-acquired pneumonia (CAP) or hospital-acquired pneumonia (HAP). Results Fifty-seven patients with HAP and 130 with CAP were included. The most common pathogens of HAP were Acinetobacter baumannii and Klebsiella pneumoniae, with the most prevalent antimicrobial resistance (AMR) genes being CTX-M and KPC. For CAP, the most common pathogens were Haemophilus influenzae and Staphylococcus aureus, with the most frequent AMR genes being CTX-M and VIM. Compared with routine bacterial culture, the PN panel demonstrated an 85% combined positive percent agreement (PPA) and 92% negative percent agreement (NPA) for the qualitative identification of 13 bacterial targets. PN detection of bacteria with higher levels of semi-quantitative bacteria was associated with more positive bacterial cultures. Positive concordance between phenotypic resistance and the presence of corresponding AMR determinants was 85%, with 90% positive agreement between CTX-M-type extended-spectrum beta-lactamase gene type and phenotype and 100% agreement for mecA/C and MREJ. The clinical benefit of the PN panel increased by 25.97% compared with traditional cultural tests. Conclusion The bacterial pathogens and AMR identified by the PN panel were in good agreement with conventional cultivation, and the clinical benefit of the PN panel increased by 25.97% compared with traditional detection. Therefore, the PN panel is recommended for patients with CAP or HAP who require prompt pathogen diagnosis and resistance identification.
Læs mere
Tjek på PubMed
136
Evaluation and clinical practice of pathogens and antimicrobial resistance genes of BioFire FilmArray Pneumonia panel in lower respiratory tract infections
Infection, 21.12.2023
Tilføjet 21.12.2023
Abstract Background Existing panels for lower respiratory tract infections (LRTIs) are slow and lack quantification of important pathogens and antimicrobial resistance, which are not solely responsible for their complex etiology and antibiotic resistance. BioFire FilmArray Pneumonia (PN) panels may provide rapid information on their etiology. Methods The bronchoalveolar lavage fluid of 187 patients with LRTIs was simultaneously analyzed using a PN panel and cultivation, and the impact of the PN panel on clinical practice was assessed. The primary endpoint was to compare the consistency between the PN panel and conventional microbiology in terms of etiology and drug resistance, as well as to explore the clinical significance of the PN panel. The secondary endpoint was pathogen detection using the PN panel in patients with community-acquired pneumonia (CAP) or hospital-acquired pneumonia (HAP). Results Fifty-seven patients with HAP and 130 with CAP were included. The most common pathogens of HAP were Acinetobacter baumannii and Klebsiella pneumoniae, with the most prevalent antimicrobial resistance (AMR) genes being CTX-M and KPC. For CAP, the most common pathogens were Haemophilus influenzae and Staphylococcus aureus, with the most frequent AMR genes being CTX-M and VIM. Compared with routine bacterial culture, the PN panel demonstrated an 85% combined positive percent agreement (PPA) and 92% negative percent agreement (NPA) for the qualitative identification of 13 bacterial targets. PN detection of bacteria with higher levels of semi-quantitative bacteria was associated with more positive bacterial cultures. Positive concordance between phenotypic resistance and the presence of corresponding AMR determinants was 85%, with 90% positive agreement between CTX-M-type extended-spectrum beta-lactamase gene type and phenotype and 100% agreement for mecA/C and MREJ. The clinical benefit of the PN panel increased by 25.97% compared with traditional cultural tests. Conclusion The bacterial pathogens and AMR identified by the PN panel were in good agreement with conventional cultivation, and the clinical benefit of the PN panel increased by 25.97% compared with traditional detection. Therefore, the PN panel is recommended for patients with CAP or HAP who require prompt pathogen diagnosis and resistance identification.
Læs mere
Tjek på PubMed
137
Biofilm formation by non-typeable Haemophilus influenzae confers resistance to complement-mediated clearance
Journal of Infectious Diseases, 20.12.2023
Tilføjet 20.12.2023
Abstract Biofilm formation is suggested to be associated with phenotype changes compared to planktonic form. We screened 1092 Haemophilus influenzae isolates for their genetic relationships and then selected 29 isolates from different genotypes and phenotypes and tested their ability to form biofilm. Our data showed a higher capacity of non-typeable isolates and particularly isolates from respiratory and genital infections to form biofilm compared to typeable isolates. This ability to form biofilm was also correlated with reduced deposition of the complement component C3b on biofilm-involved bacteria. These data suggest that the biofilm formation contributes to the virulence of non-typeable H. influenzae.
Læs mere
Tjek på PubMed
138
Pleural macrophages translocate to the lung during infection to promote improved influenza outcomes
James P. StumpffSang Yong KimMatthew I. McFaddenAndrew NishidaRoksana ShiraziYael SteuermanIrit Gat-ViksAdriana ForeroMeera G. NairJuliet MorrisonaDepartment of Microbiology and Plant Pathology, University of California, Riverside, CA 92521bDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, CA 92521cDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH 43210dInfectious Diseases Institute, The Ohio State University, Columbus, OH 43210eDepartment of Microbiology, University of Washington, Seattle, WA 98109fThe Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel
Proceedings of the National Academy of Sciences, 20.12.2023
Tilføjet 20.12.2023
139
Differences in the gut microbiota between Gurkhas and soldiers of British origin
Thomas D. Troth, Ross S. McInnes, Steven J. Dunn, Jeremy Mirza, Annalise H. Whittaker, Sarah A. Goodchild, Nicholas J. Loman, Sarah V. Harding, Willem van Schaik
PLoS One Infectious Diseases, 19.12.2023
Tilføjet 19.12.2023
by Thomas D. Troth, Ross S. McInnes, Steven J. Dunn, Jeremy Mirza, Annalise H. Whittaker, Sarah A. Goodchild, Nicholas J. Loman, Sarah V. Harding, Willem van Schaik Previous work indicated that the incidence of travellers’ diarrhoea (TD) is higher in soldiers of British origin, when compared to soldiers of Nepalese descent (Gurkhas). We hypothesise that the composition of the gut microbiota may be a contributing factor in the risk of developing TD in soldiers of British origin. This study aimed to characterise the gut microbial composition of Gurkha and non-Gurkha soldiers of the British Army. Recruitment of 38 soldiers (n = 22 Gurkhas, n = 16 non-Gurkhas) and subsequent stool collection, enabled shotgun metagenomic sequencing-based analysis of the gut microbiota. The microbiota of Gurkhas had significantly (P < 0.05) lower diversity, for both Shannon and Simpson diversity indices, using species level markers than the gut microbiota of non-Gurkha soldiers. Non-metric Multidimensional Scaling (NMDS) of the Bray-Curtis distance matrix revealed a significant difference in the composition of the gut microbiota between Gurkhas and non-Gurkha soldiers, at both the species level (P = 0.0178) and the genus level (P = 0.0483). We found three genera and eight species that were significantly enriched in the non-Gurkha group and one genus (Haemophilus) and one species (Haemophilus parainfluenzae) which were enriched in the Gurkha group. The difference in the microbiota composition between Gurkha soldiers and soldiers of British origin may contribute to higher colonization resistance against diarrhoeal pathogens in the former group. Our findings may enable further studies into interventions that modulate the gut microbiota of soldiers to prevent TD during deployment.
Læs mere
Tjek på PubMed
140
Cryo-EM structure of influenza helical nucleocapsid reveals NP-NP and NP-RNA interactions as a model for the genome encapsidation
Florian Chenavier, Leandro F. Estrozi, Jean-Marie Teulon, Eleftherios Zarkadas, Lily-Lorette Freslon, Jean-Luc Pellequer, Rob W. H. Ruigrok, Guy Schoehn, Allison Ballandras-Colas, Thibaut Crépin
Science Advances, 16.12.2023
Tilføjet 16.12.2023
141
Non-specific effects of Pneumococcal and Haemophilus vaccines in children aged 5 years and under: a systematic review
Geraghty, K., Rooney, D., Watson, C., Ledwidge, M. T., Glynn, L., Gallagher, J.
BMJ Open, 15.12.2023
Tilføjet 15.12.2023
ObjectiveTo determine the evidence for non-specific effects of the Pneumococcal and Haemophilus influenza vaccine in children aged 5 years and under. Data sourcesA key word literature search of MEDLINE, EMBASE, The Cochrane Central Register of Controlled Trials, the European Union Clinical Trials Register and ClinicalTrials.gov up to June 2023. Study eligibility criteriaRandomised controlled trials (RCTs), quasi-RCT or cohort studies. ParticipantsChildren aged 5 or under. Study appraisal and synthesis methodsStudies were independently screened by two reviewers, with a third where disagreement arose. Risk of bias assessment was performed by one reviewer and confirmed by a second. Results were tabulated and a narrative description performed. ResultsFour articles were identified and included in this review. We found a reduction in hospitalisations from influenza A (44%), pulmonary tuberculosis (42%), metapneumovirus (45%), parainfluenza virus type 1–3 (44%), along with reductions in mortality associated with pneumococcal vaccine. No data on the Haemophilus vaccine was found. Conclusions and implicationsIn this systematic review, we demonstrate that there is a reduction in particular viral infections in children aged 5 years and under who received the 9-valent pneumococcal conjugate vaccine which differ from those for which the vaccine was designed to protect against. While limited studies have demonstrated a reduction in infections other than those which the vaccine was designed to protect against, substantial clinical trials are required to solidify these findings. PROSPERO registration numberCRD42020146640.
Læs mere
Tjek på PubMed
142
[Articles] Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study
Yan Xie, Taeyoung Choi, Ziyad Al-Aly
Lancet Infectious Diseases, 15.12.2023
Tilføjet 15.12.2023
Although rates of death and adverse health outcomes following hospital admission for either seasonal influenza or COVID-19 are high, this comparative analysis shows that hospital admission for COVID-19 was associated with higher long-term risks of death and adverse health outcomes in nearly every organ system (except for the pulmonary system) and significant cumulative excess DALYs than hospital admission for seasonal influenza. The substantial cumulative burden of health loss in both groups calls for greater prevention of hospital admission for these two viruses and for greater attention to the care needs of people with long-term health effects due to either seasonal influenza or SARS-CoV-2 infection.
Læs mere
Tjek på PubMed
143
Diagnostic accuracy of a point-of-care antigen test for SARS-CoV-2 and influenza in a primary care population (RAPTOR-C19)
Thomas R. Fanshawe, Sharon TONNER, Philip J. Turner, Jade Cogdale, Margaret Glogowska, Simon De Lusignan, Cecilia Okusi, Rafael Perera, Praveen Sebastianpillai, Alice Williams, Maria Zambon, Brian D. Nicholson, F.D.Richard Hobbs, Gail N. Hayward, THE RAPTOR-C19 STUDY GROUP
Clinical Microbiology and Infection, 15.12.2023
Tilføjet 15.12.2023
Limited evidence exists for the diagnostic performance of point-of-care tests for SARS-CoV-2 and influenza in community healthcare. We carried out a prospective diagnostic accuracy study of the LumiraDx™ SARS-CoV-2 & influenza A/B assay in primary care.
Læs mere
Tjek på PubMed
144
Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age
Amber Hsiao, Arnold Yee, Bruce Fireman, John Hansen, Ned Lewis, Nicola P. Klein
New England Journal of Medicine, 14.12.2023
Tilføjet 14.12.2023
145
CDC Expands Airport Surveillance Program to More Respiratory Viruses
Journal of the American Medical Association, 14.12.2023
Tilføjet 14.12.2023
A new pilot program will monitor for respiratory viruses such as influenza and respiratory syncytial virus (RSV) in addition to SARS-CoV-2 as part of the Traveler-based Genomic Surveillance (TGS) program, the US Centers for Disease Control and Prevention (CDC) announced in a recent statement.
Læs mere
Tjek på PubMed
146
Differential effects of microRNAs miR‐21, miR‐99 and miR‐145 on lung regeneration and inflammation during recovery from influenza pneumonia
Joe Wee Jian Ong, Kai Sen Tan, Joseph Jing Xian Lee, Ju Ee Seet, Hyung Won Choi, Siok Ghee Ler, Jayantha Gunaratne, Teluguakula Narasaraju, Lok‐To Sham, Volker Patzel, Vincent T. Chow
Journal of Medical Virology, 13.12.2023
Tilføjet 13.12.2023
147
Resurgence of human metapneumovirus infection and influenza after three seasons of inactivity in the post‐COVID‐19 era in Hokkaido, Japan, 2022–2023
Yuya Fukuda, Atsuo Togashi, Satoshi Hirakawa, Masaki Yamamoto, Shinobu Fukumura, Tomohiro Nawa, Saho Honjo, Jun Kunizaki, Kouhei Nishino, Toju Tanaka, Toshitaka Kizawa, Dai Yamamoto, Ryoh Takeuchi, Yuta Sasaoka, Masayoshi Kikuchi, Takuro Ito, Kazushige Nagai, Hirofumi Asakura, Katsumasa Kudou, Masaki Yoshida, Takeshi Nishida, Takeshi Tsugawa
Journal of Medical Virology, 12.12.2023
Tilføjet 12.12.2023
148
Highly pathogenic avian influenza H5N1 virus infection of companion animals
Hinh LyDepartment of Veterinary & Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Twin Cities, MN, USA
Virulence, 9.12.2023
Tilføjet 9.12.2023
149
Combined COVID-19, Flu Vaccine Candidate Headed to Phase 3 Trials
Journal of the American Medical Association, 6.12.2023
Tilføjet 6.12.2023
An investigational messenger RNA (mRNA)–based vaccine designed to protect against both influenza and COVID-19 induced virus-specific immune responses in people who received it, manufacturers Pfizer and BioNTech announced in a press release.
Læs mere
Tjek på PubMed
150
Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States
Clinical Infectious Diseases, 5.12.2023
Tilføjet 5.12.2023
AbstractBackgroundTwo prefusion F protein-based vaccines, Arexvy and Abrysvo, have been authorized by the US Food and Drug Administration for protecting older adults against respiratory syncytial virus (RSV)-associated lower respiratory tract illness. We evaluated the health benefits and cost-effectiveness of these vaccines.MethodsWe developed a discrete-event simulation model, parameterized with the burden of RSV disease including outpatient care, hospitalization, and death for adults aged 60 years or older in the United States. Taking into account the costs associated with these RSV-related outcomes, we calculated the net monetary benefit using quality-adjusted life-year (QALY) gained as a measure of effectiveness and determined the range of price-per-dose (PPD) for Arexvy and Abrysvo vaccination programs to be cost-effective from a societal perspective.ResultsUsing a willingness-to-pay of $95 000 per QALY gained, we found that vaccination programs could be cost-effective for a PPD up to $127 with Arexvy and $118 with Abrysvo over the first RSV season. Achieving an influenza-like vaccination coverage of 66% for the population of older adults in the United States, the budget impact of these programs at the maximum PPD ranged from $6.48 to $6.78 billion. If the benefits of vaccination extend to a second RSV season as reported in clinical trials, we estimated a maximum PPD of $235 for Arexvy and $245 for Abrysvo, with 2-year budget impacts of $11.78 and $12.25 billion, respectively.ConclusionsVaccination of older adults would provide substantial direct health benefits by reducing outcomes associated with RSV-related illness in this population.
Læs mere
Tjek på PubMed